Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 379, Issue 9815, 2012, Pages 528-536

  Hanney, Marisa ^a   Prasher, Vee ^b   Williams, Nicola ^c   Jones, Emma L ^a   Aarsland, Dag ^d   Corbett, Anne ^e   Lawrence, Dale ^b   Yu, Ly Mee ^c   Tyrer, Stephen ^f   Francis, Paul T ^a   Johnson, Tony ^g   Bullock, Roger ^h   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Birmingham Dental School   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e ALZHEIMER'S SOCIETY   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g MRC BIOSTATISTICS UNIT   (United Kingdom)

^h Kingshill Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; CARDIOVASCULAR DISEASE; COGNITION; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DOWN SYNDROME; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL FUNCTION; MORTALITY; MULTICENTER STUDY; NEOPLASM; NEUROLOGIC DISEASE; NORWAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; TREATMENT DURATION; UNITED KINGDOM; UROGENITAL TRACT DISEASE;

EID: 84857055024     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61676-0     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention (CDC) Improved national prevalence estimates for 18 selected major birth defects - United States, 1999-2001 MMWR Morb Mortal Wkly Rep 54 2006 1301 1305
2. ML Margallo-Lana, C Ballard, C Morris, D Kay, S Tyrer, B Moore Cognitive decline in Down syndrome Arch Neurol 60 2003 1024
3. ML Margallo-Lana, PB Moore, DW Kay et al. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology J Intellect Disabil Res 51 2007 463 477 (Pubitemid 46746073)
4. AJ Holland, J Hon, FA Huppert, F Stevens Incidence and course of dementia in people with Down's syndrome: findings from a population-based study J Intellect Disabil Res 44 2000 138 146 (Pubitemid 30386552)
5. JK Morris, E Alberman Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register BMJ 339 2009 b3794
6. CJ Epstein Down's syndrome: critical genes in a critical region Nature 441 2006 582 583 (Pubitemid 43927280)
7. J Park, EJ Yang, JH Yoon, KC Chung Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome Mol Cell Neurosci 36 2007 270 279 (Pubitemid 47418617)
8. N Schupf, WB Zigman, MX Tang et al. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome Neurology 75 2010 1639 1644
9. J Wegiel, K Dowjat, W Kaczmarski et al. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome Acta Neuropathol 116 2008 391 407
10. EL Jones, M Margallo-Lana, VP Prasher, CG Ballard The extended tau haplotype and the age of onset of dementia in Down syndrome Dement Geriatr Cogn Disord 26 2008 199 202
11. DE Kuhn, GJ Nuovo, AV Terry Jr et al. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains J Biol Chem 285 2010 1529 1543
12. M Mohan, PK Carpenter, C Bennett Donepezil for dementia in people with Down syndrome Cochrane Database Syst Rev 1 2009 CD007178
13. M Mohan, C Bennett, PK Carpenter Rivastigmine for dementia in people with Down syndrome Cochrane Database Syst Rev 1 2009 CD007658
14. M Mohan, C Bennett, PK Carpenter Galantamine for dementia in people with Down syndrome Cochrane Database Syst Rev 1 2009 CD007656
15. R McShane, AA Sastre, N Minakaran Memantine for dementia Cochrane Database Syst Rev 2 2006 CD003154
16. W Danysz, CG Parsons, HJ Mobius, A Stoffler, G Quack Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action Neurotoxicity Res 2 2000 85 97
17. D Risser, G Lubec, N Cairns, M Herrera-Marschitz Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome Life Sci 60 1997 1231 1237 (Pubitemid 27191762)
18. TN Behar, CA Colton Redox regulation of neuronal migration in a Down Syndrome model Free Radic Biol Med 35 2003 566 575 (Pubitemid 37101124)
19. B Begni, L Brighina, L Fumagalli et al. Altered glutamate uptake in peripheral tissues from Down syndrome patients Neurosci Lett 343 2003 73 76 (Pubitemid 36581879)
20. AM Salarbaks, CM Boomkamp-Snoeren, E van Puijenbroek, PA Jansen, RJ van Marum Cardiac effects of cholinesterase inhibitors: a reason for restraint? Tijdschr Gerontol Geriatr 40 2009 79 84
21. AC Costa, JJ Scott-McKean, MR Stasko Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test Neuropsychopharmacology 33 2008 1624 1632 (Pubitemid 351684704)
22. N Rueda, M Llorens-Martín, J Flórez et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome J Alzheimers Dis 21 2010 277 290
23. J Lockrow, H Boger, H Bimonte-Nelson, AC Granholm Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome Behav Brain Res 221 2011 610 622
24. PD Mehta, SP Mehta, B Fedor, BA Patrick, M Emmerling, AJ Dalton Plasma amyloid β protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome Neurosci Lett 342 2003 155 158 (Pubitemid 36570341)
25. R Koenker, KF Hallock Quantile regression J Econ Perspect 15 2001 143 156 (Pubitemid 33594780)
26. M Rachidi, C Lopes Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome Am J Intellect Dev Disabil 115 2010 83 112